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A novel role for atypical MAPK kinase ERK3
in regulating breast cancer cell morphology
and migration
Rania Al-Mahdi1, Nouf Babteen2, Kiruthikah Thillai2, Mark Holt3, Bjarne Johansen1, Hilde Ljones Wetting1,
Ole-Morten Seternes1, and Claire M Wells2,*
1Department of Pharmacy; UiT The Arctic University of Norway; Tromsø, Norway; 2Division of Cancer Studies; New Hunts House; Guy’s Campus; King’s College London;
London, UK; 3Randall Division for Cell and Molecular Biophysics and Cardiovascular Division; King’s College London; London, UK
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ERK3 is an atypical Mitogen-activated protein kinase (MAPK6). Despite the fact that the Erk3 gene was originally
identiﬁed in 1991, its function is still unknown. MK5 (MAP kinase- activated protein kinase 5) also called PRAK is the only
known substrate for ERK3. Recently, it was found that group I p21 protein activated kinases (PAKs) are critical effectors
of ERK3. PAKs link Rho family of GTPases to actin cytoskeletal dynamics and are known to be involved in the regulation
of cell adhesion and migration. In this study we demonstrate that ERK3 protein levels are elevated as MDA-MB-231
breast cancer cells adhere to collagen I which is concomitant with changes in cellular morphology where cells become
less well spread following nascent adhesion formation. During this early cellular adhesion event we observe that the
cells retain protrusive activity while reducing overall cellular area. Interestingly exogenous expression of ERK3 delivers a
comparable reduction in cell spread area, while depletion of ERK3 expression increases cell spread area. Importantly, we
have detected a novel speciﬁc endogenous ERK3 localization at the cell periphery. Furthermore we ﬁnd that ERK3
overexpressing cells exhibit a rounded morphology and increased cell migration speed. Surprisingly, exogenous
expression of a kinase inactive mutant of ERK3 phenocopies ERK3 overexpression, suggesting a novel kinase independent
function for ERK3. Taken together our data suggest that as cells initiate adhesion to matrix increasing levels of ERK3 at the
cell periphery are required to orchestrate cell morphology changes which can then drive migratory behavior.
Introduction
Cancer cell metastasis represents the greatest threat to cancer
patient mortality. Cancer cell migration and adhesion are essential
processes during metastatic spread. Cell migration depends on the
coordinated regulation of dynamic rearrangements of the actin cyto-
skeleton accompanied by modifications in cell matrix adhesions
which together drive the cellular shape changes that are observed dur-
ing migration.1,2 Indeed cancer cells are reported to modify their
shape and stiffness to interact with the surrounding tissue in order to
migrate.3 Moreover, cell migration speed is controlled in part by the
turnover rates of adhesion and dissociation between cells.3 It is well
established that Rho family GTPases control cell migration and par-
ticipate in the regulation of cancer metastasis. The Rho family
GTPases, including Rho, Rac, and Cdc42 specifically regulate actin
cytoskeletal dynamics and cell adhesion.4,5 and are known to induce
morphological shape changes in cells.6,7 Cancer cells are thought to
exhibit cellular plasticity whereby cell movement can be either indi-
vidual (mesenchymal or rounded-amoeboid) or collective.8 In mes-
enchymal-type movement cells are more elongated9,10 and display
Rac-driven actin-rich protrusions9-11 whereas in rounded-amoeboid
movement, the cells have a rounded morphology with no obvious
polarity. Here high levels of actomyosin contractility driven by Rho-
ROCK and JAK-STAT3 facilitates elevated cells migratory speeds
compared with elongated- mesenchymal cells.9,10,12 During metasta-
sis cells are thought to be able to modify their shape (mesenchymal
versus rounded) in response the physical barriers presented by the
microenvironment. Indeed, formation of rounded-amoeboid cells
can enhance tissue invasion, and its movement has been widely pro-
moted as a tumor cell migration strategy.13,14 In vitro mesenchymal
migration of recently plated cells have been described in two phases.
Initially cells adhere and become elongated. Thereafter, the cell body
tends to contract to generate traction force that leads to gradual for-
ward gliding of the cell body. The speed generated bymigration cycle
is controlled by turnover rates of adhesion and dissociation between
cells. In contrast, rounded-amoeboid cells change their shape by rap-
idly protruding and retracting extensions that have been described as
pseudopods (false feet).15 and their movement results from alternat-
ing cycles of morphological expansion and contraction driven by
cytoskeletal dynamics, shape change, and low cellular adhesion.16
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The Rho family GTPases are known to deliver regulation of actin
cytoskeletal dynamics via the interaction with downstream effectors
in both normal and neoplastic cells.17 The group I p21 activated
protein kinases (PAKs) are among the best-known effectors of
Cdc42 and Rac1.18-20 Furthermore, PAKs are associated with tumor
progression.21 Many potential targets have been identified for group
one PAKs,22-24 but an interesting new substrate for mammalian
PAK1–3 is the atypical MAP kinase ERK3.25,26 ERK3 together
with ERK4 are considered to be atypical members of the MAP
kinase family. This is due to the fact that both proteins lack the
canonical Thr-X-Tyr motif found in the activation loop of the classi-
cal MAP kinases and they have a unique C-terminal extension. The
activation loop of ERK3 and ERK4 consists of a Ser-Gly-Glu with
Ser as a single phosphorylation site. This serine in ERK3 is constitu-
tively phosphorylated by the group one PAKs in resting cells and its
phosphorylation is not changed in response to extracellular stimuli
that activates the classical MAP kinases.25,26 ERK4 is a relatively sta-
ble protein, while ERK3 is considered as non-stable protein and is
rapidly degraded by the ubiquitin proteasome pathway.27,28 To date
the physiological function of ERK3 is unclear. However, genetic
ablation of the Erk3 gene has revealed that ERK3 plays an important
role in fetal growth and lung maturation.29 The only identified
ERK3 substrate is MAPK-activated protein kinase-5 (MK5 or
PRAK).30 MK5 was demonstrated not only to act as a substrate for
ERK3, but activated MK5 is also able to phosphorylate ERK3 both
in vitro and in vivo,30 indeed the interaction between ERK3 and
MK5 regulates the stability of ERK3.30 Several experimental studies
has shown that MK5 is involved in a wide range of biological
processes including cytoskeletal rearrangement by F-actin
remodeling31-33 and tumor suppression.34 However, a role for
ERK3 in cell adhesion and/or migration has not been investigated.
In this study we demonstrate that ERK3 protein levels are ele-
vated as MDA-MB-231 breast cancer cells adhere to collagen I,
which is concomitant with changes in cellular morphology where
cells become less well spread following nascent adhesion forma-
tion. We further show that exogenous expression of ERK3 deliv-
ers a comparable reduction in cell spread area, while depletion of
ERK3 expression increases cell spread area. Furthermore, we find
that ERK3 overexpressing cells exhibit an increased cell migra-
tion speed. Surprisingly, exogenous expression of a kinase inac-
tive mutant of ERK3 phenocopies ERK3 overexpression
suggesting a novel kinase independent function for ERK3. Taken
together our data suggest that as cells initiate adhesion to matrix,
increasing levels of ERK3 at the cell periphery are required to
drive cell morphology changes which can then drive migratory
behavior.
Results
MDA-MB-231 cells show a significant decrease in spread
area following nascent adhesion
The MDA-MB-231 breast cancer cell line is routinely used to
study adhesion, migration and invasion events. However, we found
that the morphological response of MDA-MB-231 cells following
initial adhesion to collagen I has not been previously characterized.
To explore the morphological response of MDA-MB-231 cells we
fixed and stained cells plated on collagen I for up to 8 hours (Fig. 1).
Cell shape analysis revealed that as cells are forming nascent adhesions
the cell perimeter and spread area significantly decreases but concom-
itantly the cell becomes more polarized (as revealed by the elongation
ratio). We were surprised to find that cells exhibited a reduced cell
area following plating and wondered
whether this was reflected by a lack
of protrusive activity in these cells.
To test protrusive activity we made
time-lapse movies of cells immedi-
ately following plating on collagen I.
Using in-house software specifically
designed to measure protrusive activ-
ity over time we were able to ascer-
tain that despite the reduction in
spread area all cells exhibit protrusive
activity –indeed the rate of protrusive
activity increases over time (Fig. 2).
Thus the cells are exhibiting dynamic
changes in the actin cytoskeleton as
well as increased levels of contractility
as nascent adhesions are replaced by
moremature migratory adhesions.35





have suggested a function for
Figure 1. MDA-MB-231 cells show a signiﬁcant decrease of relative spread area after 8 hours of seeding. (A)
MDA-MB-231 cells were seeded onto collagen I coverslips for the following time course 2, 4, 6, 8 hours and
were ﬁxed and stained with TRITC-phalloidin to show F-actin and Dapi. Images were taken by confocal
microscopy. (B) Cell spread area, perimeter and elongation ratio were calculated using ImageJ (NIH) soft-
ware. The results shown are mean § s.e.m of over 30 cells from each population in each of three separate
experiments. Statistical signiﬁcance was analyzed using the student test, *P  0 .05 and **P  0 .005. Scale
bar: 10 mm.



























ERK3 in cytoskeletal dynamics. This suggestion comes from the
discovery of ERK3 as a substrate for the group one p21 activated
kinases, which have been implicated in cell spreading37 and the
observation that ERK3 can regulate the expression of matrix met-
alloproteinases MMP2, 9 and 10 through phosphorylation of the
transcriptional co-activator SRC-3.25,26,36 The biological activity
of ERK3 is thought to be regulated through its cellular abun-
dance.28 Thus, having identified that there is a dramatic shift in
cell morphology within the first 8 hours of cell plating we pro-
ceeded to analyze the level of ERK3 expression over this time
frame. MDA-MB-231 were seeded on collagen I and lysed at
appropriate time points as dictated by our spreading analysis
(Fig. 1). We find that ERK3 levels are significantly increased
during the adhesion, spread area reduction and polarization
phase (Fig. 3A-B). Thus suggesting a direct correlation between
ERK3 expression levels and changes in cellular morphology,
where ERK3 expression levels were highest in the more rounded
cells, which had been adhered to the substratum for 8 hours.
Moreover, increased ERK3 protein levels following 8 hours of
cell seeding were independently reproducible in a second cell line
(Fig. S1A). In agreement with previous publication38 we were
able to confirm that the increase in ERK3 expression is post-
translational.(Fig. S1B).
ERK3 is localized at the cell periphery
Our data (Figs. 1 and 2) suggest that ERK3 may influence
cellular morphology. We therefore sought to determine the sub-
cellular distribution of ERK3 in our cells. MYC-tagged ERK3
was transiently expressed in MDA-MB-231 cells and the subcel-
lular localization observed by confocal microscopy. As expected a
significant proportion of MYC-ERK3 was distributed in the
nucleus,27,39,40 however we were also able to detect MYC-ERK3
at the periphery of the cells (Fig. 3C). We confirmed the periph-
eral localization of ERK by also detecting GFP-tagged ERK3 at
the cell periphery (Fig. S1C) and ultimately by detecting endoge-
nous ERK protein localized at the cell periphery (Fig. S1D).
Thus confirming that overexpression had not influenced the
ERK3 localization. Taken together these data demonstrate that a
significant proportion of ERK3 is localized in the periphery of
the cells at the plasma membrane. Given our finding that ERK3
expression levels are positively correlated with substratum adhe-
sion we also sought to define the localization of ERK3 during
nascent adhesion. Interestingly while MYC-ERK3 can be clearly
detected at the cell periphery following 8 hours adhesion
(Fig. 3D), a mutant ERK3 (MYC-ERK3S189A) which cannot
be phosphorylated by PAK1 cannot be detected.(Fig. 3E).
Exogenous expression of ERK3 can induce morphological
changes
Given that ERK3 protein levels are modulated as cells
undergo morphological changes and ERK3 is localized at the cell
periphery, we reasoned that ERK3 might play a role in regulating
cell shape changes. To test this hypothesis we overexpressed either
GFP-ERK3 or MYC-ERK3 in MDA-MB-231 cells and tested
the impact on cell spread area and shape. Interestingly cells over-
expressing ERK3 regardless of the tag induced a reduction in cell
spread area. Furthermore, exogenous expression of ERK3 (likely
to be higher than levels generated by collagen adhesion) also
induced cell rounding (Fig. 4A-B), a morphology that was not
induced by exposure to transfection reagent alone (Fig. S1E).
Moreover, the impact of ERK3 overexpression could also be
detected in a second breast cancer cell line; MCF-7 where a
reduction in cell spread area and cell elongation was also detected
(Fig. 4C). Thus ERK3 is able to drive morphology changes in
cells.
ERK3 overexpression drives increased cell migration speed
Cell morphology changes are intrinsically linked to cell migra-
tion potential as F-actin rearrangement, cell adhesion modifica-
tion and cell polarization are all processes associated with cellular
motility.1 Given that overexpression of ERK3 induces a reduced
spread area and decreases cell elongation we speculated that these
Figure 2. Cell protrusion activity increases as MDA-MB-231 cells adhere
to collagen. (A) Representative images of movie stills (tD0 and tD192
mins) from a movie of MDA-MB-231 imaged following plating on colla-
gen I. Phase contrast to reveal cell outline detection (see materials and
methods) and red/green pseudocolour to reveal areas of protrusion
(green) and retraction (red). (B) Quantiﬁcation of mean protrusion per
unit perimeter over time. ND2 movies (20 cells). Images were quantiﬁed
using in house MathematicaTM software.



























cells may have an increased migratory speed, as has been sug-
gested in melanoma.12 We have used Time-lapse microscopy to
observe and track the movement of the GFP-ERK3 transfected
cells. Tracking analysis of GFP-ERK3 transfected cells revealed
that ERK3 overexpressing cells exhibit an increase in mean cell
migration speed compared to control cells (Fig. 5A). The GFP-
ERK3 cells were moving with a mean cell speed of § s.e.m. D
2.822§0.2213 mm/min, un-transfected cells § s.e.m. D
2.012§0.1558 mm/min and GFP
transfected cells § s.e.m. 227§
0.2187 mm/min. Changes in cell
morphology and cell migration
speed could be driven by changes
in actin cytoskeletal dynamics.
We therefore made a detailed
examination of the F-actin rear-
rangement in control and overex-
pressing cells. We did indeed find
that ERK3 overexpressing cells
lost prominent actin stress fibers
at the cell periphery and displayed
an increase in peripheral ruffling
(Fig. 5B) which was not induced




We have already demonstrated
that exogenous expression of
ERK3 induces the same morpho-
logical changes in MDA-MB-231
and MCF-7 cells (Fig. 4C). We
therefore proceeded to test if over-
expression of ERK3 could also
promote migration in MCF-7
cells. A routine measure of MCF-
7 motility is the cell scattering
assay.41 Immunofluorescence
observations of MYC-ERK3
expressing cells suggested that
these cells were more likely to be
distant from the cell colony (sepa-
rated cells) (Fig. 6A). We there-
fore scored control and MYC-
ERK3 expressing cells for the cell
scattering event (cells have moved
away from the colony and are
complete separate). Our quantifi-
cation revealed that while only
9.8% of wild-type cells were clas-
sified as separated 41.7% of
MYC-ERK3 cells were separated
from the cell colonies (Fig. 6B).
Thus exogenous expression of
ERK3 promoted cell migration in
a second cell line.
Depletion of ERK3 results in an increase in cell spread area
Our data strongly suggest that ERK3 can mediate changes in
cellular morphology. Given that ERK3 expression increases fol-
lowing cell plating on collagen I we next tested whether the cell
shape changes we had observed (Fig. 1) could be maintained in
cells depleted of ERK3 expression. We therefore generated
Figure 3. ERK3 increasing level is coincided with the signiﬁcant decrease of relative spread area. (A) MDA-
MB-231 cells were seeded onto collagen I coated six-well plate and harvested at the following time course 2,
4, 6, 8 hours and probe for endogenous ERK3. The ﬁgure shown is a representative of three separate experi-
ments. (B) Relative intensity was calculated for the time course blot 2, 4, 6, 8 hours and analyzed using stu-
dent test. The ﬁgure shown is a representative of three separate experiments. (C) Overexpressed ERK3
localizes mainly in the nucleus and at the plasma membrane of the cell. MDA-MB-231 cells were transfected
with MYC-ERK3 for 24 hours, ﬁxed and stained with TRITC-phalloidin for F-actin (red) and MYC tag as
required (green). (D) MDA-MB-231 cells were transfected with MYC-ERK3 or (E) MYC-ERK3S189A for 24 hours.
The transfected cells were then seeded onto collagen I plates for the following time course 2, 4, 6, 8 hours
and were ﬁxed and stained with TRITC-phalloidin to show F-actin and Dapi. For ERK3 detection (green), ERK3
monoclonal antibody was used followed by Alexa Flour 488 anti-mouse. Confocal images were taken. Scale
bar: 10 mm.




























depleted of ERK3 expression
(Fig. 7A). Control (LUCKD)
and ERK3 depleted cells
(ERK3KD) were seeded onto col-
lagen I over an 8 hours time
course as previously described
(Fig. 1). Cells were stained for F-
actin (Fig. 7B) and cell images
quantified for cell spread area and
elongation as before (Fig. 1B and
Fig. 7C). We find that control
cells exhibit a reduction in cell
spread area over time concomitant
with an increase in cell elonga-
tion. In contrast ERK3KD cells
initially exhibit a reduced spread
area but over time continue to
spread and by 6h have an
increased spread area compared to
control cells. Thus suggesting that
ERK3 is required to deliver
reduced spread area 8h post plat-
ing. Interestingly, both control
and ERK3 depleted cells elongate
over time, indeed ERK3KD cells
have a significant increase in elon-
gation ratio over control cells at
8h post plating (Fig. 7C). These
observations suggest that ERK3
expression is not only required to
reduce spread area but also to pre-
vent hyper-elongation of the cells.
To further validate these observa-
tions a siRNA rescue experiment
was performed using a cross spe-
cies42-44 rescue construct
(zfERK3) that would not be tar-
geted by shRNAi sequences pres-
ent in the ERK3KD cells.
Importantly we first established
that overexpression of zfERK3
induces cell rounding as described
for HuERK3 (Fig. S1G and
Fig. 4) thus demonstrating it is
functional in MDA-MB-231 cells.
Subsequently, we found that
siRNA resistant zfERK3 expres-
sion in ERK3KD cells abrogated
the hyper-elongation exhibited by
ERK3KD cells and reduced the
spread area to control levels
(Fig. 7D-E). Indeed, zfERK3 was
also clearly localized to the cell
periphery following nascent adhe-
sion formation (Fig. 7D). Having
Figure 4. Over expression of ERK3 in different breast cell lines induces a reduction in spread area and elonga-
tion ratio. (A) MDA-MB-231 cells were transfected with GFP control vector or GFP-ERK3 for 24 hours, the cells
were than ﬁxed and stained with TRITC-phalloidin for F-actin and Dapi. (B) MDA-MB-231 Cells were trans-
fected with MYC-ERK3 for 24 hours, the cells were than ﬁxed and stained with TRITC-phalloidin for F-actin,
Dapi and MYC tag as required. (C) MCF-7 cells were transfected with MYC-ERK3 for 24 hours, the cells were
than ﬁxed and stained with TRITC-phalloidin for F-actin, Dapi and MYC tag as required. All relative spread
area and elongation ratio were calculated using ImageJ (NIH) software. The results shown are mean § s.e.m
of over 30 cells from each population in each of three separated experiments. Statistical signiﬁcance values
were calculated using Student’s t-test, *P  0.05, **P  0 .005 and ***P  0.0005.
Figure 5. ERK3 has induced the MDA-MB-231 cells mobility and the actin cytoskeleton rearrangement. (A)
MDA-MB-231 cells were transfected with GFP control vector or GFP-ERK3 for 24 hours. Cell images were col-
lected using a Sensicam (PCO Cook) CCD camera, taking a frame every 5 minutes for 16 hours from each of
the six wells using AQM acquisition software. Subsequently, cells were tracked using AQM tracker. Over 10
cells were tracked over six separate ﬁlms from three separate experiments for each experimental condition.
Mathematical analysis was then carried out using Mathematica 6.0TM workbooks (ANOVA). Mean track
speeds for each condition were compared using the Student’s T-test, **P  0 .005. (B) MDA-MB-231 cells
were transfected with MYC-ERK3 for 24 hours, the cells were than ﬁxed and stained with TRITC-phalloidin
for F-actin, Dapi and MYC tag as required. Images of F-Actin were taken using Time-lapse microscopy. An
increase of ERK3 level has an effect in F-Actin organization.



























established that overexpression of ERK3 can induce cell rounding
and increased mean cell migration speed we next tested whether
depletion of ERK3 influenced migratory behavior. In contrast to
overexpression of ERK3, cells depleted of ERK3 exhibited a
mean migration speed that was not significantly different from
control cells (Fig. 7F-G). Thus suggesting that the enhanced
elongation of ERK3KD cells observed in (Fig. 7C) does not
impede cell migration.
ERK3 driven morphological changes are not kinase
dependent
Our data suggest that ERK3 can drive cell morphology
changes that translate into changes in cell migration potential
(Fig. 4 and 5). ERK3 is an atypical Mitogen-activated protein
kinases (MAPK6) and its only known physiological function is
to phosphorylate and activate MK5.30 It has been previously
established that a kinase dead mutant MYC-ERK3D171A is
incapable of MK5 activation.30,45 We therefore proceeded to test
the requirement for ERK3 kinase activity during ERK3-induced
MDA-MB-231 cell morphological changes. MDA-MB-231 cells
were transfected with kinase-dead mutant MYC-ERK3D171A
and the spread area and elongation ratio were calculated using
ImageJ. We were surprised to discover that overexpression of
MYC-ERK3D171A also induced a significant reduction in cell
spread area indeed greater than that seen with overexpression of
MYC-ERK3 (Fig. 8). Moreover, exogenous expression of MYC-
ERK3D171A also reduced cell elongation to a comparable level
with exogenous expression of MYC-ERK3 (Fig. 8). These data
suggest that ERK3 mediated morphological changes are not
mediated via phosphorylation of MK5 or any other as yet
unidentified substrate.
Discussion
Very little is known about the physiological role of the atypi-
cal MAP kinase ERK3. In this study we identify specific
morphological changes in cell
spread area and cell shape as
MDA-MB-231 breast cancer cells
adhere to a collagen I substratum.
Whereby cells become less well
spread following nascent adhesion
formation but exhibit enhanced
elongation. We proceed to corre-
late these morphological changes
with an increase in ERK3 protein
levels and further show that exog-
enous expression of ERK3 delivers
a comparable reduction in cell
spread area, while depletion of
ERK3 expression increases cell
spread area. In addition, we find
that rounded ERK3 overexpress-
ing cells exhibit an increased cell
migration speed. The unexpected
observation that overexpression of a kinase deficient ERK3
mutant phenocopies wild-type ERK3 suggests a novel kinase
independent function for ERK3. Taken together our data suggest
that as cells initiate adhesion to matrix increasing levels of ERK3
at the cell periphery are required to drive cell morphology
changes which can then drive migratory behavior.
Our detailed analysis of MDA-MB-231 cells plated onto col-
lagen I has revealed that the cells exhibit a morphology plasticity
that ultimately leads to smaller more polarized cells with high lev-
els of protrusive activity. We would hypothesize that this behav-
ior renders the cells able to begin efficient 2D migration. We
have found that ERK3 is playing a role in this initial modulation
of cell morphology where cells with a loss of ERK3 expression
are unable to adopt the same morphological shape as control
cells. In our studies ERK3 is required to protect the cell from
hyper-elongation and we would speculate that this requirement is
attributable to a role for ERK3 in cell contractility; a hypothesis
supported by the changes in cell shape and migration observed in
ERK3 overexpressing cells as discussed below.
Several recent studies have suggested a function for ERK3 in
cell migration.25,26,32,36 This suggestion comes from the discov-
ery of ERK3 as a substrate for the group one p21 activated kin-
ases and the observation that ERK3 can regulate the expression
of matrix metalloproteinases MMP2, 9 and 10 through phos-
phorylation of the transcriptional co-activator SRC-3.25,26,36
ERK3 protein is known to have a short half-life compared to
other MAPKs and its biological activity is thought to be regulated
through its cellular abundance.28 Our data suggests the cells spe-
cifically increase ERK3 protein levels during early phase cell
adhesion and polarization an increase that was reproducible
across cell lines. Indeed, a similar increase in ERK3 protein
expression has been observed in all of the cells lines we have
tested and is also observed (although at lower level) when cells
are plated on fibronectin or ordinary plastic tissue culture dishes
(data not shown). Moreover, Crowe et al also observed that plat-
ing of squamous cell carcinoma cells onto collagen IV gave rise
to increase in ERK3 protein expression.38
Figure 6. ERK3 transfected cells tend to dissociate from neighboring cells. (A) MCF-7 cells were transfected
with MYC-ERK3 for 24 hours, the cells were then ﬁxed and stained with TRITC-phalloidin for F-actin, Dapi and
MYC tag as required. ERK3 transfected cells lose their contact with other cells. (B) The percentage of MCF-7
cells that had been detected to be dissociated. 41.7% of cells were totally isolated, 46.6% cells were partially
separated and 11.6% were within the colony. Scale bar: 10 mm.



























Interestingly we find that this rise in endogenous ERK3 pro-
tein level coincidences with a decrease in the cell spread area,
perimeter and increase in the cell elongation ratio. The rise in
ERK3 levels is likely to be due to an increase in ERK3 stability
that is induced upon cell plating. The source of this increased sta-
bility is not yet known but could involve re-localization of ERK3
to the periphery and/or phosphorylation via PAK. In contrast it
could also involve an as yet unidentified interaction partner that
protects ERK3 from ubiquitination28 following cell plating.
Our work points to a role for
ERK3 in cell contractility, mediat-
ing constraint of the cell periphery.
While one study has suggested a ERK3 localization in the Golgi/
ER-Golgi intermediate compartment (ERGIC).46 many studies
have reported that ERK3 is constitutively localized into the cyto-
plasmic and nuclear compartments.28,39 However none have
described a peripheral localization close to the plasma membrane
that might be required for driving cell contractility. The cytoplasmic
distribution of ERK3 is known to be dependent on nuclear export
and the nucleoplasmatic shuttling of ERK3 is required for some of
its biological functions.39 Co-expression of ERK3 with its
Figure 7. The depletion of ERK3 pro-
tein induces an increasing in spread
area and elongation ratio. (A) ERK3
was knocked down in MDA-MB-231
cells. For control LUC protein was
knocked down (see material and
methods) (B) MDA-MB-231 cells were
seeded onto collagen I coverslips for
the following time course 2, 4, 6,
8 hours and were ﬁxed and stained
with TRITC-phalloidin to show F-actin
and Dapi. Cells were imaged by Time-
lapse microscopy. (C) Cell spread
area, perimeter and elongation ratio
were calculated using ImageJ (NIH)
software. The results shown are
mean § s.e.m of over 30 cells from
each population in three separate
experiments. Statistical signiﬁcance
was analyzed using the student test,
*P 0 .05 and **P 0 .005. Scale bar:
10 mm. (D) LUCKD, ERK3KD and
ERK3KD cells transfected to express
Flag-zfERK3 (Flag-zfERK3-ERK3KD)
were seeded onto collagen I cover-
slips for 8 hours, ﬁxed and stained
with TRITC-phalloidin to show F-actin,
Dapi and Flag tag as required. (E) Cell
spread area and elongation ratio of
LUCKD, ERK3KD and Flag-zfERK3-
ERK3KD were calculated using
ImageJ (NIH) software. The results
shown are mean § s.e.m of over 30
cells from each population in three
separate experiments. Statistical
signiﬁcance was analyzed using the
student test, *P  0 .05 and ***P  0
.0005. Scale bar: 10mm. (F) LUCKD
and ERK3KD cells were seeded on
collagen I wells and cell images col-
lected for 16 hours using AQM acqui-
sition software. Cell track plots for
LUCKD and ERK3KD cells with all
tracked plotted from 0,0 are illus-
trated (G) Individual cells were
tracked and the mean migration
speed and persistence of direction
was calculated using in house Mathe-
maticaTM software.



























physiological partner MK5 results in re-localization of both proteins
in the cytoplasm. This re-localization of ERK3 and MK5 is depen-
dent on a direct protein-protein interaction between the two pro-
teins via ERK3 phosphorylation at serine 189. The only known
kinases that are able to phosphorylate ERK3 at serine 189 are the
group one PAK25,26 and inhibition of group one PAK results in
nuclear accumulation of ERK3.25 However, the subcellular distribu-
tion of ERK3 has so far almost exclusively been studied using ectopi-
cally expressed ERK3.39,40,47 Using a monoclonal antibody we were
able to detect endogenous ERK3
both in the nucleus and in the cyto-
plasm, but more importantly we
were also able to detect a specific
localization of ERK3 in the periph-
ery close to the cell membrane. Sim-
ilar localization was also observed
with ectopically expressed ERK3.
This localization of ERK3 close to
the cell membrane is compatible
with a function for the kinase in cell
spreading and migration. Indeed,
we were able to show a distinct
peripheral localization of ERK3 at
the cell periphery following nascent
adhesion formation that required
phosphorylation at serine 189.
However, the interaction partners
for ERK3 in the cell periphery
remain to be elucidated. Due to
technical limitations it is not possi-
ble to image endogenous localization
of MK5. Although, a recent study identified MK5 as an in situ sub-
strate for focal adhesion kinase (FAK).48 Interestingly MK5 is tyro-
sine phosphorylated during cell adhesion and this phosphorylation
induces localization at focal adhesions.48 However, localization of
MK5 to the focal adhesion occurs within the first two hours follow-
ing plating so does not coincide with our observed increase in ERK3
levels and thus disappear at the same time as the ERK3 protein level
start to increase. It is possible that ERK3 is recruited to the MK5-
Src complex at the focal adhesion later in the adhesion response and
become tyrosine phosphorylated by Src48 and this give rise to both
increased ERK3 stability and inability to activate MK5. Thus in our
cells ERK3 is localized to areas of the cell that can deliver increased
contractility.
We have observed that overexpression of ERK3 induces cell
rounding and changes in the actin cytoskeleton configuration.
While studies have linked the ERK3 substrate, MK5 to actin cyto-
skeletal dynamics.31,32 this is the first report of a direct influence
by ERK3. Moreover, our studies suggest that this function is not
mediated via phosphorylation of and activation of MK5.
Although we cannot rule out the possibility that ERK3 functions
to stabilize MK5 and allow downstream activation of MK5 via
interaction with ERK4 and/or p38.47,49 How ERK3 could deliver
a change is cellular contractility is currently unknown. MK5 activ-
ity has been linked to regulation of a Rho family GEF,50 but not
specifically to contractility while there are no other known sub-
strates for ERK3. The Rho-ROCK signaling pathway is known to
be involved in actomyosin contractility and associated with
rounded-amoeboid cells9,10 thus it would be of interest to explore
whether there is any functional relationship between ERK3 and
the Rho pathway. In contrast, PAKs are a family of proteins with
strong links to regulation of the actin cytoskeleton.21 Indeed,
PAKs are downstream effectors of Rac1 which is known to be acti-
vated when cells are plated on an extracellular matrix.17,51 It is
interesting to note that PAKs are known to drive the association of
Figure 8. ERK3 kinase activity has no effect on MDA-MB-231 cell morphology alteration. MDA-MB-231 cells
were transfected with either MYC-ERK3 or a Kinase dead mutant MYC-ERK3 (MYC-ERK3D171A). After
24 hours, the cells were ﬁxed and stained with TRITC-phalloidin for F-actin, Dapi and MYC tag as required.
Cell spread area and elongation ratio were calculated using ImageJ (NIH) software. The results shown are
mean § s.e.m of over 30 cells from each population in each of three separate experiments. Statistical signiﬁ-
cance was analyzed using the student test, *P  0 .05 and **P  0 .005 and ***P  0 .0005.
Figure 9. ERK3 activity during nascent adhesion. As cells adhere to colla-
gen I, Rac is activated, activated Rac binds to PAK1 and induces phos-
phorylation of ERK3 at serine189 – phosphorylation leads to peripheral
localization of ERK3 (green). Phosphorylation also leads to interaction
with MK5 although this may not be part of the ERK3 morphological
response. Localization of ERK3 at the cell periphery is required for the
morphological changes that occur during nascent adhesion.



























MK5 and ERK3 via serine189 phosphorylation.30 It is therefore
conceivable that Rac induced phosphorylation of ERK3 via PAK
could be a signaling event during cell shapes changes following
adhesion formation (Fig. 9). Indeed, PAK1 mediated phosphory-
lation is known to re-localize ERK3 to the cytoplasm and we now
find that phosphorylation at serine 189 is required for peripheral
localization following nascent adhesion. ERK3KD cells were
unable to deliver a reduction in cell spread area following plating,
which supports a role for ERK3 in mediating this morphological
event. Interestingly the ERK3KD cells ultimately exhibited
increased elongation compared to controls cells suggesting that
under normal physiological conditions ERK3 localized at the cell
periphery is required to prevent hyper-elongation.
We observed that overexpression of ERK3 could induce cell
rounding and also increase mean migration speed of the MDA-
MB-231 cells. This is the first recorded observation of a direct
effect of ERK3 expression on cell migration. Cancer cells have
been reported to adopt differential modes of migration (mesen-
chymal and amoeboid types)52 and it has been observed that the
less adherent rounded/amoeboid like cancer cell exhibits an ele-
vated cell migration speed.53 It is therefore not surprising that
ERK3 induced round cells displayed an increased mean migra-
tion speed. Our data suggest that ERK3 mediated rounding is
not dependent on kinase activity, and thus the increase in cell
migration speed is also likely to be kinase independent. We can-
not rule out however, that ERK3 performs an MK5 stability
function, indeed, MK5 activity has been associated with cell
motility,32,33,54 where depletion of MK5 impaired chemotaxis.
Indeed, the function of ERK3 downstream of PAK activation
maybe to localize MK5 to the cell periphery. Our data led us to
expect that depletion of ERK3 expression might inhibit cell
migration, however we found that ERK3KD cells exhibited nor-
mal migration speeds. Although unexpected it is perhaps not that
surprising. We have identified a specific role for ERK3 during
cell plating whereby ERK3 is required to orchestrate specific cell
morphology changes. Such morphology changes are not necessar-
ily required during random migration. Furthermore, we have
observed that ERK3 induced rounded cells display an increase in
cell migration speed but this does not necessarily mean that a
more mesenchymal shaped cell, as observed for ERK3KD, would
exhibit a cell migration speed lower then control. Indeed, elon-
gated mesenchymal cells are able to efficiently migrate.9,10 It may
be that ERK3KD cells would exhibit migration defects in a more
constrained environment where increased cellular contractility is
required, such a migration through a 3D matrix.55-57 Comple-
mentary to our random migration studies we also observed that
ERK3 overexpression was able to drive MCF-7 cell scattering, a
cellular response known to be mediated by PAK activation,58
suggesting that ERK3 mediated cell morphological changes are
not restricted to one cell type.
Conclusion
We have clearly demonstrated an important specific role for
ERK3 in mediating cell morphological changes. Furthermore,
we were able to accurately localize endogenous ERK3 to the cell
periphery. We found that both cells overexpressing ERK3 and
ERK3 knockdown cells exhibited significant changes in spread
area and elongation ratio compared to control cells. Moreover, in
two different migration assays overexpression of ERK3 increased
cell migration potential. ERK3 mediated cell morphology
changes were found to be independent of MK5 activation. We
speculate from our results and previous work that activation of
RAC during nascent cell adhesion and subsequent cell migration
promotes the localization of ERK3 at the cell periphery via
PAK1 phosphorylation. ERK3 localized at the cell periphery is
able to mediate the cell morphological changes associated with
recently plated cells and also drive cell migration speed via
increased cell rounding. These ERK3 functions may be the result
of interaction with MK5 or via an as yet undefined molecular
pathway. Thus we have identified a novel function for ERK3
that may have important consequences for therapeutic interven-
tion of cancer cell invasion.
Materials and Methods
Immunoblotting and antibodies
MDA-MB-231 and MCF-7 cells were lysed for 10 minutes in
lysis buffer (0.5% NP-40, 30 mM sodium pyrophosphate,
50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1 mM EDTA,
50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 10 mg/ml leupep-
tin, 1mM DTT and 1 mg/ml aprotinin) and were cleared by cen-
trifugation at 13,000 g for 10 minutes at 4C. Equal amounts of
protein were analyzed by 7.5% SDS-polyacrylamide gels then
transferred into nitrocellulose membranes (Schleicher and
Schell). Western blotting was performed by blocking nitrocellu-
lose membranes with 5% skim milk in 1XTBST buffer for
1 hour, followed by overnight incubation with primary antibody
at 4C and 1 hour incubation with the appropriate secondary
antibody at room temperature. Blots were developed by
enhanced chemiluminescence (ECL, Amersham Pharmacia). The
MAPK6 (ERK3) monoclonal antibody (M02), clone (4C11) was
purchased from Abnova. The 9E10 c-Myc (sc-40) was purchased
from Santa Cruz Biotechnology. Monoclonal anti-Flag
(cat#1804), clone (M2) was purchased from Sigma Aldrich.
Alexa Fluor 488 goat anti-mouse IgG (A-11001) and Cy5 goat
anti-mouse IgG (A10524) were purchased from (Invitrogen).
Both polyclonal goat anti-mouse and anti-rabbit immunoglobu-
lins HRP secondary antibodies were purchased from Dako. p44/
42 MAPK (ERK1/2) antibody was purchased from Cell Signal-
ing and PRAK (MK5) (A-7) monoclonal antibody (sc-46667)
was purchased from Santa Cruz.
DNA constructs
The following construction pSG5ERK3-Myc (MYC-ERK3),
pSGERK3D171A-Myc (MYC-ERK3D171A) and pSGERK
3S189A-Myc (MYC-ERK3S189A) had been described previ-
ously.30,45 EGFP-ERK3 (GFP-ERK3) was generated by cloning
the EcoRI-SalI fragment from pGBKT7-ERK3.59 in the corre-
sponding sites of pEGFP-C1 (Clontech). The zebrafish ERK3



























was amplified from the image clone (IMAGE:9038031) using
primers 50- ggcgaattcatcacagaatggcagagaaatttgaaagc-3and 5-
gcggatccttacttatcgtcgtcatccttgtaatcatttaaatgcttgaaaatgctgc -3 and
subcloned as an EcoRI-BamHI fragment into pSG5 vector (Stra-
tagene) generating pSG5-Flag-zfERK3. Note that at the protein
level zfERK3 and HuERK3 have 95% amino acid sequence simi-
larity in the kinase domain.
shRNA
shRNA against ERK3 was cloned in the retroviral vector L193
RRI-GreenattR1ccdBCmRattR2 (kindly provided from Dr D.
Micklem, University of Bergen). The procedures are described in
Henriksen JR et al. study.60 The following sequence was used for
ERK3 shRNA (hairpin in lower case): GGCTTTTCATGTAT
CAGCTTTCaagcttCAAAGCTGATACATGAAAAGCC
The negative control shRNA against Luc was cloned in the
same vector and was kindly provided from Dr. C. Einvik, Uni-
versity of Tromsø.
Viral transduction
Phoenix AMPHO cells were transfected with the retroviral
constructs using calcium phosphate precipitation. Forty-eight
hours after transfection the supernatant was harvested mixed
with 5ug/ml protamine sulfate and used to infect recipient cells.
Stable knockdown cell lines were selected from the infected cells
by growing them in presence of 1ug/ml puromycin.
Cell culture and transfection
MDA-MB-231 (American Type Culture Collection (ATCC)
HTB-26), MCF-10 (ATCC CRL-10317), MCF-7 (ATCC
HTB-22), HeLa (ATCC CCL-2TM), 293T/17 [HEK 293T/
17] (ATCC CRL-11268TM) and Phoenix AMPHO cells
(ATCC CRL-3213) were maintained in Dulbecco’s Modified
Eagle’s Medium from Sigma-Aldrich (D 5796) supplemented
with 10% fetal bovine serum, penicillin (100 units/ml), and
streptomycin (100 mg/ml). Lipofectamine 2000 (Invitrogen)
reagent was used to transfect the MDA-MB-231 and MCF-7
cells according to the manufacturer’s instructions.
Immunofluorescence and image analysis
Cells were seeded at a density of 5£104 cells/ml on collagen
I (BD Biosciences) coated coverslips for overnight. To detect
the morphological changes in ERK3 transfected cells, cells were
transfected with either MYC-ERK3 or GFP-ERK3 for over-
night. All cells were subsequently fixed with 4% paraformalde-
hyde in PBS for 20 minutes at room temperature and then
permeabilised with 0.2% Triton X-100 in PBS for 5 minutes.
The cells were than blocked with 3% bovine serum albumin in
PBS for 30 minutes. Following incubation, cells were washed
three times in PBS. For the detection of ERK3, primary anti-
body was diluted in PBS (1:50) containing 0.5% bovine serum
albumin and was incubated for 2 hours at room temperature.
The cells were then washed three times in PBS and incubated
with the secondary antibody along with Rhodamine phalloidin
(Invitrogen) diluted in PBS (1:1000) for 1 hour at room tem-
perature. For cell morphology detection, images were taken
using Olympus 1X71. For ERK3 localization and stabilization,
images of cells were obtained using a Zeiss LSM510 confocal
laser-scanning microscope (Zeiss, Welwyn Garden City, UK),
using the accompanying LSM 510 software. Cell spread area
(area), elongation ration (circularity) and perimeter were ana-
lyzed using ImageJ (NIH) program. Data are presented as mean
§ s.e.m. The Student paired t-test was used to compare differ-
ences between groups. Statistical significance was accepted for P
 0 .05.
Time-lapse microscopy
Time-lapse microscope was also used to display a movie
were cells had been tracked. MDA-MB-231 cell were seeded
on 6-well plates, containing control or experimental cells as
described in the figure legends, were placed on the automated
stage of a Olympus 1X71 in the presence of 10% CO2. Cell
images were collected using a Sensicam (PCO Cook) CCD
camera, taking a frame either every 3 minutes for 8 hours or
5 minutes for 16 hours from each of the 6 wells using AQM
acquisition software (Andor Technology, Belfast, UK). Subse-
quently, all the acquired time-lapse sequences were displayed
as a movie and cells were tracked for the whole of the time-
lapse sequence using AQM tracker (Andor Technology, Bel-
fast, UK).
Cell protrusion activity analysis
Outlines of cells and cell clumps were determined using
our own bespoke image processing routines in Wolfram
Mathematica 10 (Champaign, IL). These outlines were filled
so that cells were represented as white objects on a black
background. Consecutive images were combined in to an
RGB image such that the first frame constituted the red
channel and the next time frame was the green channel. The
blue channel was left blank. Thus, red pixels represented
regions that had undergone retraction, while green regions
represented regions that had undergone protrusion. Regions
of overlap (yellow) were converted to gray. This was done for
each consecutive pair of images in a temporal stack. Protru-
sion and retraction indices were calculated on a per image
basis by counting the number of red and green pixels and
divided by the available cellular perimeters as determined
from the detected cellular outlines.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was isolated from cells using the RNeasy Plus kit
from Qiagen according to the manufacturer’s recommendations.
Quantity and purity of the extracted RNA was determined using
the NanoDrop spectrophotometer (Thermo Fisher Scientific),
and mRNA expression levels were quantified by reverse transcrip-
tion quantitative PCR (RT-qPCR) performed on a Stratagene
MX3000P instrument. Reverse transcription of total RNA was
performed using Reverse Transcriptase Core Kit (Eurogentec)
with random nonamer primers according to the manufacturer’s
recommendations.
Primer pairs were purchased from Sigma Life Science.
Primer specificities and absence of primer dimers were



























determined by SYBR green melting curve analysis. cDNA was
amplified for 40 cycles in a 25 ml SYBR green PCR mix
(Brilliant II SYBR Green QPCR Master Mix, Stratagene)
containing 300 nM of each primer. Cycling conditions: 95C
for 10 minutes, 40 cycles at 95 C for 30 seconds, and 60C
for 1 minute. Duplicate reverse transcriptase reactions were
performed for each RNA sample, and duplicate PCR analyses
were performed on each cDNA sample. The absence of geno-
mic DNA was confirmed by performing a no reverse tran-
scriptase (NoRT) control, and the absence of contaminations
was assessed by including a no template control (NTC). The
delta-delta Cq method.61 was used to determine the relative
amount of target mRNA in the samples normalized against
the average expression of the two reference genes ACTB and
TFRC.
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